Gallipoli

Researchers are conducting an Italian multicenter, observational, prospective study to gather information on patients with bone metastases. The study aims to establish a National Bone Metastasis Database by collecting detailed data from all patients with bone metastases referred to participating centers. This effort helps track and understand the condition better over a long period. Patients with bone metastases from solid tumors will be registered in a specially designed online database created for this study. Each enrolled patient will be entered into this database and followed over time until death or until follow-up is stopped for any other reason. This approach allows researchers to monitor the disease progression and treatment outcomes using a centralized digital system. Participants will provide informed consent to be part of the study. Their medical data, including diagnosis information, will be collected and stored in the database. This process includes ongoing monitoring and follow-up assessments as available during the study, which may last up to 15 years. The main outcome is the creation and maintenance of the comprehensive National Bone Metastasis Database to support research and patient care.

Researchers are investigating treatments for men with metastatic castration-resistant prostate cancer who have previously received chemotherapy. The main goal is to compare overall survival between participants treated with xaluritamig and those receiving either cabazitaxel or a second androgen receptor-directed therapy. This is a Phase 3, open-label, randomized study focusing on patients with progressive disease confirmed by imaging and specific clinical criteria. Participants will be randomly assigned to receive either xaluritamig by short-term intravenous infusion or the investigator's choice of cabazitaxel infusion or oral androgen receptor-directed therapies such as abiraterone or enzalutamide. The study includes participants who have had prior treatment with androgen receptor-directed therapy and one taxane chemotherapy in the metastatic castration-resistant setting. Treatments are given according to protocol with monitoring and adjustments as needed. During the study, participants will undergo assessments including imaging scans to confirm disease progression, laboratory tests to monitor organ function and testosterone levels, and performance status evaluations. Researchers will track overall survival for up to approximately 53 months. Safety will be closely monitored throughout the study, and participants must have a life expectancy of at least 12 weeks to enroll. The total duration of participation depends on treatment response and survival outcomes.